1.Impacts of Patient Care on Doctor-patient Trust-Field Studies Based on Capital City Tertiary Hospitals
Chumeng GAO ; Xiaoyang WANG ; Zhaofeng LYU ; Rui GUO ; Lanqiu LIU ; Jia YANG ; Taoxin MO ; Jingnan MIAO ; Yifan LI
Chinese Medical Ethics 2015;(5):699-702
Objective:To understand the status of outpatients′medical care and their impact on the doctor -pa-tient trust in Beijing .Methods:Three tertiary hospitals were selected due to most concentrated high -quality medi-cal resources , the largest number of patient visits , universalism and particularism trust could be compared , taking field observations , personal interviews and questionnaires methods .Results:The main factors affecting clinical doctor-patient trust are time, the doctor skills, medical ethics, medical and prescription drug division , etc.are appropriate and effective .Conclusion:Play the role of pyramidmedical system′s overall effectiveness , and es-tablish a patient-centered system for outpatient care as soon as possible a comprehensive grasp of the overall con -struction team doctor , continue to strengthen the standardized management of medication .
2.Partial penectomy combined with penis lengthening to treat penile cancer.
Tao JIANG ; Quanlin LI ; Chunzhang GAO ; Xishuang SONG ; Zhaofeng WANG ; Quanzhong DING
National Journal of Andrology 2004;10(4):309-310
We used the method of partial penectomy combined with penis lengthening to treat 2 cases of penile cancer. The penile lengths were lengthened by 3-4 cm. This method could retain the penis and sexual function to the maximum degree. And a few patients could avoid total penectomy and micturate on their feet. This operation is very simple and safe, with no complication.
Aged
;
Humans
;
Male
;
Middle Aged
;
Penile Neoplasms
;
surgery
;
Penis
;
surgery
3.Correlation of ARK5 expression in peripheral blood circulating tumor cells with curative efficacy and prognosis for gemcitabine chemotherapy in pancreatic cancer patients
Zhaofeng GAO ; Wei GUO ; Xiaodan YANG ; Xiaorong LIU ; Lingyu HU ; Xiaoguang WANG
Chinese Journal of Pancreatology 2023;23(5):330-334
Objective:To detect the expression of ARK5 in peripheral blood circulating tumor cells (CTCs) from pancreatic cancer patients and explore its correlation with the efficacy and prognosis for gemcitabine chemotherapy.Methods:A total of 175 peripheral blood samples of pancreatic cancer patients who were treated in the Department of Hepatobiliary Surgery, Second Affiliated Hospital of Jiaxing University from January 2016 to June 2021 were collected. CTCs were enriched by nano-microfluidic chip technology. The expression of ARK5 in CTCs was detected by immunofluorescence. According to the expression of ARK5, the patients were divided into two groups: positive group and negative group. The differences on clinicopathological features, the efficacy of chemotherapy, median survival and progression-free survival time between the two groups were compared.Results:CTCs were enriched in 98 of 175 patients (55.6%), including 70 ARK5 positive and 28 ARK5 negative patients. There were no significant differences on clinical features between the two groups, and the two groups were comparable. In the 70 ARK5 positive patients, 64 patients (91.4%) were resistant to gemcitabine, while only 12 of the 28 ARK5 negative patients (42.8%) were resistant to gemcitabine. The incidence of gemcitabine resistance in ARK5 positive patients was significantly higher than that in ARK5 negative patients, and the difference was statistically significant ( P<0.001). The median survival time was 11.5 months in ARK5 positive group and 14 months in ARK5 negative expression group, and the progression-free survival time was 6 months in ARK5 positive expression group and 8 months in negative expression group. The survival time of ARK5 positive group was significantly shorter than that of ARK5 negative group, and the difference was statistically significant ( P<0.05). Conclusions:The pancreatic cancer patients with ARK5 positive CTCs have significantly higher incidence of gemcitabine resistance and shorter survival time than those with ARK5 negative CTCs. Detection of ARK5 expression in CTCs may be a new method to judge chemotherapy efficacy and prognosis for pancreatic cancer patients.